No Fast Track For Lecanemab In EU Disappoints Eisai
Pan-EU Approval Could Come In March 2024, Says Company
Despite being hailed as a potential breakthrough for Alzheimer’s, the EMA will not fast-track lecanemab, underscoring differences with the US FDA’s frequent use of accelerated pathways.
